NCT06273111 (TSTIH) is a EARLY_PHASE1 clinical trial of 5% simvastatin ointment in Hemangioma Skin, sponsored by Joyce Teng.

Who is sponsoring NCT06273111?

NCT06273111 is sponsored by Joyce Teng.

What drugs are being tested in NCT06273111?

Interventions in NCT06273111: 5% simvastatin ointment.

What condition does NCT06273111 study?

NCT06273111 studies Hemangioma Skin.

Is NCT06273111 still recruiting?

NCT06273111 is currently status unknown. Last updated 22 February 2024.

Last reviewed 2024-02-22 · How we verify

NCT06273111: TSTIH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Simvastatin for Treating Infantile Hemangioma

Status unknown EARLY_PHASE1 Last updated 22 February 2024

What this trial tests

EARLY_PHASE1 trial testing 5% simvastatin ointment in Hemangioma Skin in 12 participants. Status unknown.

Timeline

1 April 2024

Primary endpoint
31 July 2025

31 December 2025

Quick facts

Lead sponsor	Joyce Teng
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 April 2024
Primary completion	31 July 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

5% simvastatin ointment — full drug profile →

Conditions studied

Hemangioma Skin — all drugs for Hemangioma Skin →

Sponsor

Joyce Teng — full company profile →

Who can join

Adults 3 Months to 5, any sex, with Hemangioma Skin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 24-week, open-label pilot study to evaluate the safety and preliminary efficacy of 5% simvastatin ointment in treating 12 children with superficial IH. The primary objective: To evaluate the safety and tolerability of topical treatment with 5% simvastatin ointment for superficial IH over 24 weeks. The secondary objective: 1.1 To evaluate the efficacy of 5% simvastatin ointment when topical treatment is administered twice daily for 24 weeks. Evaluation is performed at each clinic visit via investigator global assessment (IGA) based on standardized 3D digital photography and hemangioma activity score (HAS). 1.2 To evaluate the impact of 5% simvastatin ointment on quality of life using the IH-QoL questionnaire.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted medical therapies for vascular anomalies.
Borst A. · · 2024 · cited 1× · PMID 39644074 · DOI 10.1182/hematology.2024000599

Verify or expand the search:

Other Joyce Teng trials

Trials by the same sponsor.

NCT03269474 — Computational Drug Repurposing for All EBS Cases · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06273111 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Joyce Teng
Last refreshed: 22 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06273111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing